Attached files
| file | filename |
|---|---|
| 10-Q - QUARTERLY REPORT - Tribute Pharmaceuticals Canada Inc. | tbuff_10q.htm |
| EX-31.2 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc. | tbuff_ex312.htm |
| EX-31.1 - CERTIFICATION - Tribute Pharmaceuticals Canada Inc. | tbuff_ex311.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Tribute Pharmaceuticals Canada Inc. | Financial_Report.xls |
| EX-32.2 - CERTIFICATION PURSUANT - Tribute Pharmaceuticals Canada Inc. | tbuff_ex322.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Tribute Pharmaceuticals Canada Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Rob Harris, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
November 14, 2013
|
By:
|
/s/ Rob Harris | |
|
Rob Harris
|
|||
|
Chief Executive Officer
|
|||